Copyright
©2011 Baishideng Publishing Group Co.
World J Hepatol. Nov 27, 2011; 3(11): 278-284
Published online Nov 27, 2011. doi: 10.4254/wjh.v3.i11.278
Published online Nov 27, 2011. doi: 10.4254/wjh.v3.i11.278
Table 1 Clinical and biological characteristics of 24 hepatitis C virus patients with low and high grade B cell-non Hodgkin’s lymphoma
Sex | Age(yr) | HCV RNA log10 (UI/mL) | HCVgenotype | Duration of HCV-infection (mo) | Ishak(grading) | Ishak(staging) | Type of lymphoma | Stage | Extranodal | Cryoglobulin | Bcl2/Bcl6 | |
1 | F | 70 | 5.90 | 2a/2c | 21 | 4 | 0 | Marginal extranodal (MALT) | IV | Orbit/BM | Positive | +/- |
2 | F | 69 | 5.40 | 2a | 19 | 12 | 6 | Marginal extranodal (MALT) | IV | Parotid/BM | Positive | -/- |
3 | F | 64 | nd | 2 | 25 | nd | nd | Marginal extranodal (MALT) | IV | Orbit/BM | Positive | na |
4 | M | 36 | nd | 2 | 7 | 6 | 1 | Splenic marginal | IV | Spleen/BM | Negative | -/- |
5 | F | 72 | 6.00 | 1b | 22 | 8 | 2 | Splenic marginal | III | Spleen | Negative | -/- |
6 | F | 65 | nd | 2a/2c | nd | nd | nd | Splenic marginal | IV | Spleen/BM | Negative | -/- |
7 | F | 70 | 5.90 | 2 | nd | 8 | 1 | Marginal nodal | IV | BM | Positive | -/- |
8 | F | 55 | 5.07 | 2a/2c | 31 | 17 | 6 | Follicular lymphoma | III | None | na | +/+ |
9 | M | 67 | 6.80 | 2a | 30 | 6 | 0 | Follicular lymphoma | IV | Liver/BM | Negative | +/- |
10 | F | 59 | nd | 2 | 20 | 16 | 6 | Follicular lymphoma | III | None | Negative | +/+ |
11 | F | 78 | nd | 2a | 30 | nd | nd | Lymphoplasmocytoid lymphoma | IV | BM | Positive | na |
12 | M | 61 | nd | 1b | 18 | 5 | 2 | DLBCL | IV | BM | na | na |
13 | M | 29 | 7.80 | 1a | 4 | 6 | 0 | DLBCL | II | None | Negative | +/+ |
14 | M | 66 | 6.70 | 1b | nd | 12 | 6 | DLBCL | Liver, Lung | na | na | |
15 | M | 62 | 6.90 | 1a | 10 | nd | nd | DLBCL | IV | BM | na | na |
16 | M | 56 | 5.1 | 1b | nd | nd | nd | DLBCL | IV | BM | na | na |
17 | F | 55 | 5.4 | 1b | nd | nd | nd | DLBCL | IV | Liver | na | na |
18 | F | 59 | 6.4 | 1a/1b | nd | nd | nd | DLBCL | IV | Lung/BM | na | +/+ |
19 | M | 65 | 5.8 | 1b | 11 | 10 | 2 | DLBCL | IV | Lung | Negative | +/+ |
20 | M | 46 | nd | 1b | 6 | 8 | 1 | DLBCL | IV | Liver | Negative | +/+ |
21 | M | 51 | 6.3 | 1b | 15 | 10 | 2 | DLBCL | IV | Lung/BM | Negative | -/- |
22 | M | 49 | 5.9 | 3 | 15 | nd | nd | DLBCL | IV | Gastric | Negative | -/- |
23 | M | 78 | 6.2 | 2a/2c | 19 | 10 | 1 | DLBCL | III | None | Negative | +/+ |
24 | F | 74 | 5.0 | 1 | 16 | 10 | 4 | DLBCL | IV | Palatine Tonsil/BM | Negative | -/- |
Table 2 Comparison of biological, virological and clinical characteristics of hepatitis C virus-related low vs high grade B cell-non Hodgkin’s lymphoma
DLBCL (n = 13) | Indolent B-NHL (n = 11) | 95% CI | P value | |
Age ( yr)1 | 57 ± 12 | 64 ± 11 | -16.8 to 2.8 | 0.153 |
Sex (M/F) | 10/3 | 2/9 | - | 0.014 |
Duration of HCV infection (yr)1 | 12 ± 5 | 22 ± 7 | -15.1 to -4.9 | < 0.001 |
ALT value (UI/L)1 | 58 ± 40 | 40 ± 27 | -11.5 to 47.5 | 0.219 |
Genotype 1/not 1 | 10/3 | 2/9 | - | 0.014 |
HCVRNA log10 (UI/mL)1 | 6.1 ± 0.6 | 5.8 ± 0.3 | -0.11 to 0.71 | 0.147 |
Ishak (grading)1 | 8.4 ± 2.1 | 9.3 ± 5.0 | -4.05 to 2.25 | 0.560 |
Ishak (staging)1 | 1.5 ± 1.2 | 2.75 ± 2.7 | -2.97 to 0.47 | 0.146 |
Table 3 Results of antiviral treatment in patients with low grade B cell-non Hodgkin’s lymphoma
Sex | Age (yr) | Histology | Stage | HCVRNA log10 (UI/mL) | Genotype | Staging (Ishak) | Treatment | Treatment duration (mo) | Response to treatment | Remission lymphoma | |
1 | F | 70 | Marginal extranodal | IV | 5.9 | 2a/2c | 0 | Peg 180 μg/wk + RBV 800 mg/d | 6 | SVR | Complete hematological response |
2 | F | 69 | Marginal extranodal | IV | 5.4 | 2a | 6 | Peg 180 μg/wk + RBV 800 mg/d | 6 | SVR | Complete hematological response |
3 | F | 64 | Marginal extranodal | IV | 5.6 | 1b | nd | Peg 180 μg/wk + RBV 1000 mg/d | 12 | Relapser | Progressive disease |
4 | M | 36 | Marginal splenic | IV | 5.5 | 2 | 1 | Peg 180 μg/wk + RBV 800 mg/d | 6 | SVR | Partial response |
5 | F | 72 | Marginal splenic | III | 6.0 | 1b | 2 | Peg 180 μg/wk + RBV 1000 mg/d | 12 | SVR | Partial response |
6 | F | 65 | Marginal splenic | IV | 5.6 | 2a/2c | nd | Peg 180 μg/wk + RBV 1200 mg/d | 6 | SVR | Complete hematological response |
7 | F | 70 | Marginal nodal | IV | 5.9 | 2 | 2 | Peg 180 μg/wk + RBV 800 mg/d | 6 | SVR | Complete hematological response |
8 | F | 55 | Follicular lymphoma | III | 5.0 | 2a/2c | 6 | Peg 180 μg/wk + RBV 800 mg/d | 6 | Relapser | Progressive disease |
9 | M | 67 | Follicular lymphoma | IV | 6.8 | 2a | 0 | Peg 180 μg/wk + RBV 800 mg/d | 6 | SVR | Complete hematological response |
- Citation: Pellicelli AM, Marignani M, Zoli V, Romano M, Morrone A, Nosotti L, Barbaro G, Picardi A, Gentilucci UV, Remotti D, D'Ambrosio C, Furlan C, Mecenate F, Mazzoni E, Majolino I, Villani R, Andreoli A, Barbarini G. Hepatitis C virus-related B cell subtypes in non Hodgkin's lymphoma. World J Hepatol 2011; 3(11): 278-284
- URL: https://www.wjgnet.com/1948-5182/full/v3/i11/278.htm
- DOI: https://dx.doi.org/10.4254/wjh.v3.i11.278